Process and Formulation Optimization of a Continuous Microfluidic-Based Platform for High-Quality mRNA-LNP Production

Added on:
5 Feb, 2026

Messenger RNA (mRNA) has emerged as a transformative platform for vaccines and targeted therapies due to its capacity for precise and rapid gene expression. The COVID-19 pandemic underscored both its promise and the challenges of large-scale production. In response, continuous flow manufacturing—guided by Quality by Design (QbD) principles and enabled by automation and digital technologies—offers a scalable, consistent, and efficient alternative to traditional batch production.

  • Zidi Yang
  •   The University of Sheffield Chemical, Materials and Biological Engineering
Read the publication that featured this abstract